Quantitative analysis of heparanase gene expression in esophageal squamous cell carcinoma

被引:25
作者
Ikeguchi, M
Fukuda, K
Yamaguchi, K
Kondo, A
Tsujitani, S
Kaibara, N
机构
[1] Tottori Univ, Fac Med, Div Operating Rm, Yonago, Tottori 6838504, Japan
[2] Tottori Univ, Fac Med, Div Surg Oncol, Yonago, Tottori 6838504, Japan
关键词
apoptosis; esophageal squamous cell carcinoma; heparan sulfate proteoglycans; heparanase; real-time reverse transcriptase-polymerase chain reaction;
D O I
10.1245/ASO.2003.05.022
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Heparan sulfate proteoglycans, the main components of the extracellular matrix, are recognized as important components of signal transduction and play an important role in tumor progression. Heparanase (hep) degrades heparan sulfate proteoglycans, but the clinical importance of hep is unclear. In this study, we investigated the clinicopathologic importance of hep messenger RNA (mRNA) expression in esophageal squamous cell carcinoma (ESCC). Methods: Fresh tumors and noncancerous epithelia were obtained from 57 ESCC patients after esophagectomy. Expression levels of hep and glyceraldehyde-3-phosphate dehydrogenase mRNA were quantitatively analyzed by real-time reverse transcriptase-polymerase chain reaction. Apoptotic cancer cells and microvessel density were evaluated immunohistochemically. Results: The relative hep mRNA expression level (hep: glyceraldehyde-3-phosphate dehydrogenase ratio) in ESCC was lower than in noncancerous tissue (P < .001). Tumor hep expression decreased according to tumor progression and correlated with the occurrence of apoptotic cancer cells, but not with tumor microvessel density. Moreover, low hep expression correlated with poor patient survival. Conclusions: Reduced hep mRNA expression might result in abnormal cell growth and correlate with ESCC progression.
引用
收藏
页码:297 / 304
页数:8
相关论文
共 27 条
[1]  
Cheung IY, 2001, CLIN CANCER RES, V7, P1698
[2]  
El-Assal ON, 2001, CLIN CANCER RES, V7, P1299
[3]   Heparanase as mediator of angiogenesis: mode of action [J].
Elkin, M ;
Ilan, N ;
Ishai-Michaeli, R ;
Friedmann, Y ;
Papo, O ;
Pecker, I ;
Vlodavsky, I .
FASEB JOURNAL, 2001, 15 (07) :1661-+
[4]  
Endo K, 2001, ANTICANCER RES, V21, P3365
[5]  
Ginath S, 2001, INT J ONCOL, V18, P1133
[6]  
Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO
[7]  
2-A
[8]   Esophageal cancer: The mode of lymphatic tumor cell spread and its prognostic significance [J].
Hosch, SB ;
Stoecklein, NH ;
Pichlmeier, U ;
Rehders, A ;
Scheunemann, P ;
Niendorf, P ;
Knoefel, WT ;
Izbicki, JR .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (07) :1970-1975
[9]   Identification of active-site residues of the pro-metastatic endoglycosidase heparanase [J].
Hulett, MD ;
Hornby, JR ;
Ohms, SJ ;
Zuegg, J ;
Freeman, C ;
Gready, JE ;
Parish, CR .
BIOCHEMISTRY, 2000, 39 (51) :15659-15667
[10]   Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis [J].
Hulett, MD ;
Freeman, C ;
Hamdorf, BJ ;
Baker, RT ;
Harris, MJ ;
Parish, CR .
NATURE MEDICINE, 1999, 5 (07) :803-809